<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00596687</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00005062</org_study_id>
    <secondary_id>e5062</secondary_id>
    <nct_id>NCT00596687</nct_id>
  </id_info>
  <brief_title>Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery</brief_title>
  <acronym>RABBIT 2-SX</acronym>
  <official_title>RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients With Type 2 Diabetes Undergoing General Surgery (RABBIT 2 Surgery)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High blood glucose levels in surgical patients with diabetes are associated with increased
      risk of medical complications and death. Improved glucose control with insulin injections may
      improve clinical outcome and prevent some of the hospital complications. In patients who have
      undergone surgery, high blood glucose increases the risk of wound infection, kidney failure
      and death. It is not known; however, what is the best insulin regimen in patients who will
      undergo surgery. The use of repeated injections of regular insulin is commonly used for
      glucose control in hospitalized patients with diabetes. Recently, the combination of Lantus®
      and Apidra® insulins has been shown to improve glucose control with lower rate of
      hypoglycemia (low blood sugar). We hypothesize that in patients with type 2 diabetes admitted
      to general surgery wards, treatment with once daily glargine (Lantus) plus supplemental
      glulisine insulin (Apidra®) will produce better glycemic control and a lower rate of hospital
      complications than treatment with regular insulin per sliding scale (SSRI). The present study
      aims to determine which insulin treatment is best for glucose control in hospitalized
      patients with diabetes. Glargine and glulisine insulins are approved for use in the treatment
      of patients with diabetes by the FDA.

      Subjects included in the study will have type 2 diabetes and be admitted to Grady Memorial
      Hospital, Veterans Administration Medical Center, and Emory University Hospital, Atlanta,
      Georgia. A total of ~94 patients will be recruited at each institution.

      A post-hoc cost analysis of hospitalization costs and charges of the Rabbit surgery trial
      will be completed in order to determine differences in hospitalization cost between basal
      bolus insulin and SSI regimen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Blood Glucose Concentration</measure>
    <time_frame>hospital stay days 2-10</time_frame>
    <description>blood glucose concentration in the intervention groups after second day of treatment to up to 10 days of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure># Participants With Hypoglycemic Events</measure>
    <time_frame>hospital stay days 2-10</time_frame>
    <description>number of participants in the treatment arms with of hypoglycemic events (&lt; 70 mg/dl)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">234</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Inpatient Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glargine once daily plus glulisine given before meals plus supplemental glulisine for BG &gt; 140</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sliding scale regular insulin four-times daily achs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine</intervention_name>
    <description>Insulin glargine once daily SQ</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regular insulin</intervention_name>
    <description>Sliding scale regular insulin SQ four-times daily before meals or every 6 hours if patient NPO</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Novolin R</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glulisine</intervention_name>
    <description>scheduled glulisine given SQ at mealtime TID; none given if patient NPO</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Apidra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females between the ages of 18 and 80 years admitted to a general surgery
             service.

          2. Patients admitted for non-cardiac elective or emergency surgery or trauma.

          3. A known history of type 2 diabetes mellitus &gt; 3 months, receiving either diet alone or
             any combination of oral antidiabetic agents (sulfonylureas, metformin,
             thiazolidinediones).

          4. Subjects must have an admission blood glucose &gt; 140 mg and &lt; 400 mg/dL without
             laboratory evidence of diabetic ketoacidosis (serum bicarbonate &lt; 18 mEq/L or positive
             serum or urinary ketones).

        Exclusion Criteria:

          1. Subjects with increased blood glucose concentration, but without a known history of
             diabetes (stress hyperglycemia).

          2. Subjects with a history of diabetic ketoacidosis and hyperosmolar hyperglycemic state,
             or ketonuria.

          3. Acute critical illness or CABG surgery expected to require prolonged admission to a
             critical care unit (ICU, CCU, SICU, Neuro ICU).

          4. Patients with clinically relevant hepatic disease or impaired renal function, as shown
             by a serum creatinine ≥ 3.5 mg/dl.

          5. Mental condition rendering the subject unable to understand the nature, scope, and
             possible consequences of the study.

          6. Female subjects are pregnant or breast feeding at time of enrollment into the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo Umpierrez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University SOM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Umpierrez GE, Smiley D, Jacobs S, Peng L, Temponi A, Mulligan P, Umpierrez D, Newton C, Olson D, Rizzo M. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care. 2011 Feb;34(2):256-61. doi: 10.2337/dc10-1407. Epub 2011 Jan 12.</citation>
    <PMID>21228246</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2008</study_first_submitted>
  <study_first_submitted_qc>January 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2008</study_first_posted>
  <results_first_submitted>July 9, 2013</results_first_submitted>
  <results_first_submitted_qc>February 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 12, 2014</results_first_posted>
  <last_update_submitted>February 7, 2014</last_update_submitted>
  <last_update_submitted_qc>February 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Guillermo Umpierrez</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>post-op complications</keyword>
  <keyword>inpatient hyperglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrolled patients with a BG 140-400 mg/dL with DM for more than 3 months,aged 18-80 yo, treated with diet alone, any combination of oral antidiabetic agents, or lowdose insulin in 2008-2009. Study was conducted at Grady Memorial Hospital,Emory University Hospitaland the Veterans Administration Medical Center.</recruitment_details>
      <pre_assignment_details>Exclusion criteria included hyperglycemia without a known history of diabetes, cardiac surgery, clinically relevant hepatic disease or impaired renal function (serum creatinine ≥3.0 mg/dL), history of diabetic ketoacidosis (20), pregnancy, and any mental condition rendering the subject unable to give informed consent.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Basal Bolus</title>
          <description>Glargine and rapid-acting mealtime insulin plus supplemental glulisine. A total of 0.5 units of insulin/day given, half as basal glargine insulin once a day and the other half as mealtime glulisine given three times a day at meals.</description>
        </group>
        <group group_id="P2">
          <title>SSRI</title>
          <description>Sliding scale regular insulin four-times daily if blood glucose &gt; 140 before meals and at bedtime. The sliding scale regimen was per the hospital protocol.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>&lt; 24 hours of insulin treatment</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>continuous insulin infusion during TPN</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>cancelled surgery</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Basal Bolus</title>
          <description>Glargine and rapid-acting mealtime insulin plus supplemental glulisine</description>
        </group>
        <group group_id="B2">
          <title>SSRI</title>
          <description>Sliding scale regular insulin four-times daily.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="104"/>
            <count group_id="B2" value="107"/>
            <count group_id="B3" value="211"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="12"/>
                    <measurement group_id="B2" value="57" spread="10"/>
                    <measurement group_id="B3" value="58" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title># Participants With Hypoglycemic Events</title>
        <description>number of participants in the treatment arms with of hypoglycemic events (&lt; 70 mg/dl)</description>
        <time_frame>hospital stay days 2-10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Basal Bolus</title>
            <description>Glargine and rapid-acting mealtime insulin plus supplemental glulisine</description>
          </group>
          <group group_id="O2">
            <title>SSRI</title>
            <description>Sliding scale regular insulin four-times daily.</description>
          </group>
        </group_list>
        <measure>
          <title># Participants With Hypoglycemic Events</title>
          <description>number of participants in the treatment arms with of hypoglycemic events (&lt; 70 mg/dl)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Blood Glucose Concentration</title>
        <description>blood glucose concentration in the intervention groups after second day of treatment to up to 10 days of treatment</description>
        <time_frame>hospital stay days 2-10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Basal Bolus</title>
            <description>Glargine and rapid-acting mealtime insulin plus supplemental glulisine</description>
          </group>
          <group group_id="O2">
            <title>SSRI</title>
            <description>Sliding scale regular insulin four-times daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Blood Glucose Concentration</title>
          <description>blood glucose concentration in the intervention groups after second day of treatment to up to 10 days of treatment</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145" spread="32"/>
                    <measurement group_id="O2" value="172" spread="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>during hospital days 1-10</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Basal Bolus</title>
          <description>Glargine and rapid-acting mealtime insulin plus supplemental glulisine</description>
        </group>
        <group group_id="E2">
          <title>SSRI</title>
          <description>Sliding scale regular insulin four-times daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>hypoglycemia</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia &lt; 70 mg/dl</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="104"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Guillermo Umpierrez</name_or_title>
      <organization>Emory Univ SOM</organization>
      <phone>4047781665</phone>
      <email>geumpie@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

